Date published: 2026-5-2

1-800-457-3801

SCBT Portrait Logo
Seach Input

V-ATPase D2 Inhibitors

V-ATPase D2 inhibitors represent a chemical class designed to selectively target and inhibit the activity of the V-ATPase D2 subunit, a crucial component of the vacuolar-type H+-ATPase (V-ATPase) enzyme. V-ATPases are ATP-driven proton pumps found in the membranes of various intracellular compartments and in the plasma membrane of many eukaryotic cells. They play a vital role in regulating the acidification of intracellular compartments, such as lysosomes, endosomes, and the Golgi apparatus. The inhibition of the D2 subunit by these chemicals disrupts the normal function of V-ATPase, leading to altered proton pumping and intracellular pH balance. This selective inhibition is significant because the D2 subunit is specifically involved in the assembly and operation of the V-ATPase complex, and its modulation can have profound effects on cellular processes dependent on acidification.

V-ATPase D2 inhibitors is characterized by their ability to interact with the D2 subunit of the V-ATPase complex. These inhibitors are typically small molecules that can penetrate cellular membranes to reach intracellular targets. The binding of these chemicals to the D2 subunit affects the structural integrity and function of the V-ATPase complex. This interaction specifically inhibits the proton pump mechanism of the enzyme, resulting in reduced acidification of intracellular compartments. The precise binding sites and mechanism of inhibition can vary among different inhibitors in this class, with some binding to allosteric sites and others interfering directly with the active sites of the D2 subunit. The inhibition of V-ATPase D2 can influence various cellular processes, including protein degradation, receptor-mediated endocytosis, and intracellular signaling pathways. The ability to selectively target the D2 subunit is a defining feature of this class, allowing for specific modulation of V-ATPase activity without affecting other ATPases or cellular processes not directly related to the V-ATPase function.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Bafilomycin A1

88899-55-2sc-201550
sc-201550A
sc-201550B
sc-201550C
100 µg
1 mg
5 mg
10 mg
$98.00
$255.00
$765.00
$1457.00
280
(6)

Bafilomycin A1 is a specific inhibitor of the vacuolar type H+-ATPase (V-ATPase). It binds to the V0 subunit of the enzyme, preventing proton transport and thereby disrupting acidification of intracellular compartments such as lysosomes and endosomes.

Concanamycin A

80890-47-7sc-202111
sc-202111A
sc-202111B
sc-202111C
50 µg
200 µg
1 mg
5 mg
$66.00
$167.00
$673.00
$2601.00
109
(2)

Concanamycin A, similar to Bafilomycin A1, targets the V0 subunit of V-ATPase. It inhibits proton pumping activity, leading to increased pH in acidic vesicles and altered endocytic and autophagic pathways.

Omeprazole

73590-58-6sc-202265
50 mg
$67.00
4
(1)

Though primarily known as a proton pump inhibitor for gastric acid-related disorders, Omeprazole also exhibits inhibitory effects on V-ATPase. It can indirectly influence the V-ATPase functionality by altering cellular proton dynamics.

E-64

66701-25-5sc-201276
sc-201276A
sc-201276B
5 mg
25 mg
250 mg
$281.00
$947.00
$1574.00
14
(0)

Loxistatin, or E-64-d, is a cysteine protease inhibitor that can indirectly affect V-ATPase activity. By inhibiting lysosomal proteases, it may impact the lysosomal function and thus the requirement for V-ATPase activity, indirectly modulating its action.

Geldanamycin

30562-34-6sc-200617B
sc-200617C
sc-200617
sc-200617A
100 µg
500 µg
1 mg
5 mg
$39.00
$59.00
$104.00
$206.00
8
(1)

Geldanamycin, an Hsp90 inhibitor, can indirectly influence V-ATPase activity. By inhibiting Hsp90, it affects the stability of several client proteins, potentially including those involved in the regulation or formation of V-ATPase, thus modulating its activity.

Withaferin A

5119-48-2sc-200381
sc-200381A
sc-200381B
sc-200381C
1 mg
10 mg
100 mg
1 g
$130.00
$583.00
$4172.00
$20506.00
20
(1)

Withaferin A has been observed to indirectly affect V-ATPase activity. It may modulate the expression or stability of proteins involved in V-ATPase assembly or regulation, thereby influencing the enzyme's function.

Chloroquine

54-05-7sc-507304
250 mg
$69.00
2
(0)

Chloroquine has been found to accumulate in acidic vesicles and raise their pH, indirectly inhibiting V-ATPase activity by disrupting the proton gradient necessary for its function.